Your browser doesn't support javascript.
loading
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan, Sivagurunathan; McKone, Edward F; Downey, Damian G; Duckers, Jamie; MacGregor, Gordon; Tullis, Elizabeth; Van Braeckel, Eva; Wainwright, Claire E; Watson, Danie; Ahluwalia, Neil; Bruinsma, Bote G; Harris, Christopher; Lam, Anna P; Lou, Yiyue; Moskowitz, Samuel M; Tian, Simon; Yuan, Jason; Waltz, David; Mall, Marcus A.
Afiliação
  • Sutharsan S; Department of Pulmonary Medicine, Division of Cystic Fibrosis, University Medicine Essen-Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany. Electronic address: sivagurunathan.sutharsan@rlk.uk-essen.de.
  • McKone EF; National Referral Center for Adult Cystic Fibrosis, St Vincent's University Hospital, and University College Dublin, Dublin, Ireland.
  • Downey DG; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
  • Duckers J; All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough, Cardiff, UK.
  • MacGregor G; Department of Respiratory Medicine, Queen Elizabeth University Hospital, Glasgow, UK.
  • Tullis E; St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
  • Van Braeckel E; Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
  • Wainwright CE; Queensland Children's Hospital, University of Queensland, Brisbane, QLD, Australia.
  • Watson D; Adult Cystic Fibrosis Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
  • Ahluwalia N; Vertex Pharmaceuticals, Boston, MA, USA.
  • Bruinsma BG; Vertex Pharmaceuticals, Boston, MA, USA.
  • Harris C; Vertex Pharmaceuticals, Boston, MA, USA.
  • Lam AP; Vertex Pharmaceuticals, Boston, MA, USA.
  • Lou Y; Vertex Pharmaceuticals, Boston, MA, USA.
  • Moskowitz SM; Vertex Pharmaceuticals, Boston, MA, USA.
  • Tian S; Vertex Pharmaceuticals, Boston, MA, USA.
  • Yuan J; Vertex Pharmaceuticals, Boston, MA, USA.
  • Waltz D; Vertex Pharmaceuticals, Boston, MA, USA.
  • Mall MA; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Center for Lung Research, Berlin, Germany.
Lancet Respir Med ; 10(3): 267-277, 2022 03.
Article em En | MEDLINE | ID: mdl-34942085
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrose Cística Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Child / Humans Idioma: En Revista: Lancet Respir Med Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrose Cística Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Child / Humans Idioma: En Revista: Lancet Respir Med Ano de publicação: 2022 Tipo de documento: Article